Company: HROW
Filing Date: 2025-05-08
Form Type: 10-Q
Source: 0001641172-25-009263
Chunk: 7

Company: HARROW, INC.
Filing Date: 2025-05-08
Form: 10-Q
Item: Item 1
Chunk 7
---
 its consolidated subsidiaries, unless the context indicates or otherwise requires, the “Company”
or “Harrow”) is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative
ophthalmic pharmaceutical products for the U.S. market. Harrow helps U.S. eyecare professionals preserve the gift of sight by making its
comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans
each year. The Company owns commercial rights to one of the largest portfolios of branded ophthalmic pharmaceutical products in the U.S.,
all of which are marketed under its Harrow name. The Company also owns and operates ImprimisRx, one of the nation’s leading ophthalmology-focused
pharmaceutical-compounding businesses.

Basis of Presentation

The Company has prepared the accompanying unaudited
condensed consolidated financial statements in accordance with accounting principles generally accepted in the United States of America
(“GAAP”) for interim financial information and in accordance with the rules and regulations of the U.S. Securities and Exchange
Commission. Accordingly, they do not include all of the information and footnotes required by GAAP for audited financial statements. In
the opinion of management, all adjustments (consisting of only normal recurring adjustments) considered necessary for a fair presentation
have been included. Operating results for the three months ended March 31, 2025 are not necessarily indicative of the results that may
be expected for the year ending December 31, 2025 or for any other period. For further information, refer to the Company’s audited
consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December
31, 2024.

The accompanying unaudited condensed consolidated
financial statements include the accounts of the Company and its wholly owned and majority-owned subsidiaries.

Harrow consolidates entities in which it has a
controlling financial interest. The Company assesses control under the variable interest entity (“VIE”) model to determine
whether the Company is the primary beneficiary of that entity. The Company consolidates (i) entities in which it holds and/or controls,
directly or indirectly, more than 50% of the voting rights, and (ii) VIEs for which the Company is deemed to be the primary beneficiary.
All intercompany accounts and transactions have been eliminated in consolidation.

NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The following represents an update